We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

By LabMedica International staff writers
Posted on 22 Mar 2015
Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening.

Drug discovery and development have long been hampered by high failure rates attributed to the reliance on non-human animal models employed during safety and efficacy testing. More...
A fundamental problem in this inefficient process is that non-human animal models cannot adequately represent human biology.

To circumvent the physiological differences inherent in animal model systems, investigators at the University of California, Berkeley (USA) developed a human tissue-based model system using heart cells derived from selectively manipulated human pluripotent stem cells. The cells were induced to grow in a silicon chip device that contained a three-dimensional culture scaffold that was comparable to the geometry and spacing of connective tissue fiber in a human heart. Heart cells were loaded into the chip in multiple layers aligned in a single direction. Microfluidic channels on either side of the growth area served as models for blood vessels, mimicking the exchange by diffusion of nutrients and drugs with human tissue.

Results published in the March 9, 2015, edition of the journal Scientific Reports revealed that within 24 hours after the heart cells were loaded onto the chip, they began beating on their own at a normal physiological rate of 55 to 80 beats per minute. The culture system was able to keep human induced pluripotent stem cell derived cardiac tissue viable and functional over a period of several weeks.

The system was tested by monitoring the reaction of the heart cells to four different cardiovascular drugs: isoproterenol, E-4031, verapamil, and metoprolol. Changes in the heart tissue’s beat rate were monitored to gauge the response to the compounds. The experiment was considered to be a success when—after half an hour of exposure to isoproterenol, a drug used to treat bradycardia—the heart tissue beat rate increased from 55 to 124 beats per minute.

The "heart-on-a-chip" project was sponsored in part by the [US] National Institutes of Health's Tissue Chip for Drug Screening Initiative, an interagency collaboration for the development of three-dimensional human tissue chips that model the structure and function of human organs.

“Ultimately, these chips could replace the use of animals to screen drugs for safety and efficacy,” said senior author Dr. Kevin E. Healy, professor of bioengineering at the University of California, Berkeley. “Using a well-designed model of a human organ could significantly cut the cost and time of bringing a new drug to market.”

Related Links:
University of California, Berkeley



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Experts used an OpenAI reasoning model to reanalyze 376 previously unsolved cases and surface leads for 18 diagnoses (Image credit: iStock)

AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases

Rare genetic diseases often leave families without definitive answers, even after genome sequencing and expert review. As scientific evidence evolves and clinical data remain fragmented across systems,... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.